Article

Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy.

Journal of the American Academy of Dermatology (impact factor: 3.99). 01/2007; 55(6):1092-4. DOI:10.1016/j.jaad.2006.06.031 pp.1092-4
Source: PubMed

ABSTRACT Topical therapeutic options for cutaneous squamous cell carcinoma in situ include 5-fluorouracil cream and imiquimod cream. Such treatment may be preferable to surgical or destructive modalities in certain anatomic locations and in instances where patients are unwilling or poor surgical candidates. We present 4 such patients with cutaneous squamous cell carcinoma in situ involving a digit. Each patient failed treatment with imiquimod cream as monotherapy. In addition, two patients failed treatment with 5-fluorouracil cream as monotherapy. All 4 responded completely to 5-fluorouracil and imiquimod cream as combination therapy. In patients who have failed monotherapy with a topical agent for cutaneous squamous cell carcinoma in situ, combination treatment using both topical 5-fluorouracil cream and imiquimod cream may be considered as an alternative therapeutic strategy.

0 0
 · 
1 Bookmark
 · 
18 Views
  • Source
    Article: Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
    Erika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, Wolf Hervé Fridman, Jerome Galon, Catherine Sautès-Fridman, Eric Tartour, Laurence Zitvogel, Guido Kroemer
    [show abstract] [hide abstract]
    ABSTRACT: Toll-like receptors (TLRs) have first been characterized for their capacity to detect conserved microbial components like lipopolysaccharide (LPS) and double-stranded RNA, resulting in the elicitation of potent (innate) immune responses against invading pathogens. More recently, TLRs have also been shown to promote the activation of the cognate immune system against cancer cells. Today, only three TLR agonists are approved by FDA for use in humans: the bacillus Calmette-Guérin (BCG), monophosphoryl lipid A (MPL) and imiquimod. BCG (an attenuated strain of Mycobacterium bovis) is mainly used as a vaccine against tuberculosis, but also for the immunotherapy of in situ bladder carcinoma. MPL (derived from the LPS of Salmonella minnesota) is included in the formulation of Cervarix®, a vaccine against human papillomavirus-16 and -18. Imiquimod (a synthetic imidazoquinoline) is routinely employed for actinic keratosis, superficial basal cell carcinoma, and external genital warts (condylomata acuminata). In this Trial Watch, we will summarize the results of recently completed clinical trials and discuss the progress of ongoing studies that have evaluated/are evaluating FDA-approved TLR agonists as off-label medications for cancer therapy.
    Oncoimmunology. 09/2012; 1(6):894-907.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

5-fluorouracil cream
 
alternative therapeutic strategy
 
certain anatomic locations
 
combination therapy
 
combination treatment
 
cutaneous squamous cell carcinoma
 
destructive modalities
 
digit
 
imiquimod cream
 
instances
 
monotherapy
 
patients
 
poor surgical candidates
 
situ
 
surgical
 
topical 5-fluorouracil cream
 
topical agent
 
Topical therapeutic options
 

Andrew L Ondo